Pulmo BioTech Inc. PLMO Archives

WednesdayJul 09, 2008 8:25 am

PulmoBioTech, Inc. (PLMO.OB) Introduces New Molecular Imaging Agent

In the field of nuclear medicine, it is necessary to perfect non-invasive diagnostic methods, and PulmoBioTech is contributing greatly to this need. The company recently announced the completion of bio-distribution studies concerning its PulmoBind molecular imaging agent. The process of imaging on a cellular level requires the use of specialized molecules which are chemically engineered to bind to specific cells in the body, and these are then bonded to radioactive tracers. PulmoBind is a bonding agent that has been found to surpass those traditionally used in the field on several points. Essentially, it is a totally harmless substance known as…

TuesdayJul 08, 2008 12:01 pm

Pulmo BioTech Inc. (PLMO.OB) Completes DFH-12 Studies

Pulmo BioTech Incorporated announced this week that its subsidiary, PulmoScience Incorporated, has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the lung's vascular system. The completion of this study is a milestone for the company, proving the success of their molecule, code named DFH-12, and its application in other imaging technologies. DFH-12 works, via injection, because the molecule is designed to bond only to the inner walls of the vascular system of the lungs. The DFH-12 molecule is tagged with a radionuclide, so the integrity of the lung's vascular system can…

ThursdayJul 03, 2008 12:35 pm

Pulmo BioTech Inc. (PLMO.OB) Recently Announced Potential MRI Applications for PulmoBind

Pulmo BioTech Inc. is a venture capital company focused solely on medical research, development and marketing. They are dedicated to bringing revolutionary new medical techniques and technologies to those in need of medical solutions. Recently, Pulmo BioTech announced the possibility of a new application for its PulmoBind molecular imaging technology. Pulmo believes that there are several useful applications for its product line in conjunction with traditional MRI scanners. The company announced that it has had preliminary success with also tagging its molecular imaging candidates with a magnetic resonance contrast agent. If this work is successful, it will allow the medical…

WednesdayJun 18, 2008 5:20 am

Pulmo BioTech, Inc. (PLMO.OB) is “One to Watch”

Pulmo BioTech, Inc is dedicated to bringing revolutionary medical diagnostic technologies to the market. The company’s current product base is composed of an array of molecular imaging substances developed for the diagnosis of pulmonary embolism, pulmonary hypertension, and lung inflammatory disorders. Presently, these substances are in the process of receiving regulatory approval before entering Phase I human trials. The company has used the brand name “PulmoBind” for these substances. These products have the potential to completely replace the conventional technology being used for a nuclear medicine-based diagnosis of pulmonary embolism. The substances could also create new markets for the diagnosis…

Site Search

Company Search

Tag: Pulmo BioTech Inc. PLMO

PulmoBioTech, Inc. (PLMO.OB) Introduces New Molecular Imaging Agent

Pulmo BioTech Inc. (PLMO.OB) Completes DFH-12 Studies

Pulmo BioTech Inc. (PLMO.OB) Recently Announced Potential MRI Applications for PulmoBind

Pulmo BioTech, Inc. (PLMO.OB) is “One to Watch”

Market Basics

Newsletter Publishers

Public Companies